Jaguar Health Board of Directors Authorizes Company to Include Cryptocurrency as a Treasury Reserve Asset
Jaguar Health (NASDAQ:JAGX) announced that its Board of Directors has unanimously authorized the inclusion of cryptocurrency as a treasury reserve asset. The company views this as a strategic move to diversify its treasury holdings with digital assets that offer potential upside and inflation protection.
CEO Lisa Conte revealed that several banks and an investor have approached Jaguar with cryptocurrency transaction terms. The company is currently evaluating the potential benefits for shareholders and its core development programs. Jaguar continues to focus on developing crofelemer, its plant-based prescription medicine, across three main programs: intestinal failure, cancer therapy-related diarrhea treatment, and expanding Canalevia® for dogs.
Jaguar Health (NASDAQ:JAGX) ha annunciato che il suo Consiglio di Amministrazione ha autorizzato all'unanimità l'inclusione della criptovaluta come asset di riserva di tesoreria. L'azienda considera questa mossa strategica per diversificare le proprie riserve di tesoreria con asset digitali che offrono potenziale di crescita e protezione dall'inflazione.
La CEO Lisa Conte ha rivelato che diverse banche e un investitore si sono avvicinati a Jaguar con proposte di transazioni in criptovalute. L'azienda sta attualmente valutando i benefici potenziali per gli azionisti e per i suoi programmi di sviluppo principali. Jaguar continua a concentrarsi sullo sviluppo di crofelemer, il suo farmaco a base vegetale, in tre programmi principali: insufficienza intestinale, trattamento della diarrea correlata alla terapia oncologica e l'espansione di Canalevia® per cani.
Jaguar Health (NASDAQ:JAGX) anunció que su Junta Directiva ha autorizado por unanimidad la inclusión de criptomonedas como un activo de reserva en tesorería. La compañía considera esta medida como una estrategia para diversificar sus reservas de tesorería con activos digitales que ofrecen potencial de crecimiento y protección contra la inflación.
La CEO Lisa Conte reveló que varios bancos y un inversor se han acercado a Jaguar con términos para transacciones en criptomonedas. La empresa está evaluando actualmente los posibles beneficios para los accionistas y sus programas de desarrollo principales. Jaguar sigue enfocándose en desarrollar crofelemer, su medicamento a base de plantas, en tres programas principales: insuficiencia intestinal, tratamiento de la diarrea relacionada con terapias contra el cáncer y la expansión de Canalevia® para perros.
Jaguar Health (NASDAQ:JAGX)는 이사회가 만장일치로 암호화폐를 재무 보유 자산에 포함시키는 것을 승인했다고 발표했습니다. 회사는 이를 재무 보유 자산을 다각화하고 인플레이션으로부터 보호하며 잠재적 상승 가능성이 있는 디지털 자산으로 간주하고 있습니다.
CEO 리사 콘테는 여러 은행과 투자자가 Jaguar에 암호화폐 거래 조건을 제안했다고 밝혔습니다. 회사는 현재 주주와 핵심 개발 프로그램에 대한 잠재적 이점을 평가 중입니다. Jaguar는 식물 기반 처방약인 크로펠머(crofelemer)를 장기부전, 암 치료 관련 설사 치료, 그리고 반려견용 Canalevia® 확장 등 세 가지 주요 프로그램에서 개발하는 데 집중하고 있습니다.
Jaguar Health (NASDAQ:JAGX) a annoncé que son conseil d'administration a unanimement autorisé l'inclusion de la cryptomonnaie comme actif de réserve de trésorerie. L'entreprise considère cette décision comme une stratégie pour diversifier ses avoirs en trésorerie avec des actifs numériques offrant un potentiel de croissance et une protection contre l'inflation.
La PDG Lisa Conte a révélé que plusieurs banques et un investisseur ont approché Jaguar avec des propositions de transactions en cryptomonnaie. La société évalue actuellement les avantages potentiels pour les actionnaires et ses programmes de développement principaux. Jaguar continue de se concentrer sur le développement du crofelemer, son médicament à base de plantes, dans trois programmes principaux : insuffisance intestinale, traitement de la diarrhée liée à la thérapie anticancéreuse, et l'expansion de Canalevia® pour les chiens.
Jaguar Health (NASDAQ:JAGX) gab bekannt, dass sein Vorstand einstimmig die Aufnahme von Kryptowährungen als Treasury-Reservevermögen genehmigt hat. Das Unternehmen betrachtet diesen Schritt als strategische Maßnahme zur Diversifizierung seiner Treasury-Bestände mit digitalen Vermögenswerten, die Potenzial für Wertsteigerung und Inflationsschutz bieten.
CEO Lisa Conte erklärte, dass mehrere Banken und ein Investor Jaguar mit Kryptowährungstransaktionsangeboten kontaktiert haben. Das Unternehmen prüft derzeit die möglichen Vorteile für Aktionäre und seine Kernentwicklungsprogramme. Jaguar konzentriert sich weiterhin auf die Entwicklung von Crofelemer, seinem pflanzenbasierten verschreibungspflichtigen Medikament, in drei Hauptprogrammen: Darmversagen, Behandlung von durch Krebstherapie verursachtem Durchfall und der Erweiterung von Canalevia® für Hunde.
- None.
- Exposure to volatile cryptocurrency market risks
- Potential deviation from core pharmaceutical business focus
- Uncertain regulatory environment for corporate cryptocurrency holdings
- No specified cryptocurrency allocation or strategy details provided
Strategic decision positions Jaguar to diversify treasury holdings with a long-term digital store of value
SAN FRANCISCO, CA / ACCESS Newswire / June 26, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or "the Company"), announced today that its Board of Directors has unanimously authorized the Company to include cryptocurrency as a treasury reserve asset.
"Cryptocurrencies continue to gain investor attention and acceptance as a major asset class. We believe selected cryptocurrencies could serve as a strong treasury reserve asset for the Company, diversifying our assets to include a digital store of value that we believe has significant upside potential and may also provide a safeguard against inflation," said Lisa Conte, Jaguar's Founder and CEO. "Jaguar has been approached by several banks and an investor with terms for cryptocurrency transactions. The Company is assessing the potential value to shareholders, and the potential benefits for our core development programs, of making selected cryptocurrencies a treasury reserve asset for the Company."
Jaguar's has three core development programs for crofelemer, the Company's novel plant-based prescription medicine: its orphan disease intestinal failure program; its ongoing efforts to make crofelemer available for treatment of cancer therapy-related diarrhea (CTD) in patients with metastatic breast cancer receiving selected targeted therapies; and its ongoing development program to expand access for Canalevia® (crofelemer delayed-release tablets) in dogs from the conditional approval in chemotherapy-induced diarrhea to a potential global approval for acute general diarrhea. Each of these core programs for crofelemer is the subject of business development goals of forging corporate partnerships to bring in non-dilutive funding for the Company.
About the Jaguar Health Family of Companies
Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.
For more information about:
Jaguar Health, visit https://jaguar.health
Napo Pharmaceuticals, visit www.napopharma.com
Napo Therapeutics, visit napotherapeutics.com
Magdalena Biosciences, visit magdalenabiosciences.com
Canalevia-CA1, visit canalevia.com
Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements." These include statements regarding making selected cryptocurrencies a treasury reserve asset for the Company, Jaguar's belief that selected cryptocurrencies could serve as a strong treasury reserve asset for the Company, Jaguar's belief that there may be significant upside potential in diversifying the Company's assets to include a digital store of value, Jaguar's belief that diversifying the Company's assets to include a digital store of value may provide a safeguard against inflation, the potential value to shareholders of making selected cryptocurrencies a treasury reserve asset for the Company, and the potential benefits for Jaguar's core development programs of making selected cryptocurrencies a treasury reserve asset for the Company.In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
CONTACT:
hello@jaguar.health
Jaguar-JAGX
SOURCE: Jaguar Health, Inc.
View the original press release on ACCESS Newswire
FAQ
What did Jaguar Health (JAGX) announce about cryptocurrency on June 26, 2025?
How will Jaguar Health (JAGX) implement its cryptocurrency strategy?
What are the potential benefits of JAGX's cryptocurrency initiative?
What are Jaguar Health's (JAGX) core development programs?
How many banks have approached Jaguar Health (JAGX) about cryptocurrency?
